Trial result ·
Ivonescimab plus chemotherapy as first-line treatment for advanced thymic carcinoma: preliminary results of a phase II trial with biomarker analyses.
Written based on 1 research study on PubMed, searched on 15 Nov 2026.
What was studied
This trial tested a new drug mix for thymic carcinoma. This is a rare cancer that grows fast. The 7 people had advanced cancer and no prior care for it. They got ivonescimab with paclitaxel and carboplatin every 3 weeks. After that, they kept taking ivonescimab on its own. It was a mid-stage trial at one center, and all got the same drugs. The team also looked at signs in tumor tissue and blood.
What they found
People were followed for a median of 6.4 months. In 6 of 7 people, the tumors shrank. In all people, the cancer was held in check. At 6 months, no one had died or seen the cancer grow. One person's cancer grew at 15.7 months, after side effects made them stop. Serious side effects were common, mostly a drop in a type of white blood cell. No one died from the drugs. Those whose tumors shrank a lot had a lower CD4/CD8 ratio. This ratio was measured in the blood at the start. This blood link was only a first look.
What it means for patients
The authors say the drug mix showed early signs of acting on the tumor. They say the side effects could be handled. They say the blood CD4/CD8 ratio may be tied to deep tumor shrinkage. They want this link checked in the full group of people. They also want other studies to test it.
Why it is not certain yet
Only 7 people were in this early report. The time people were followed was short. The results are still early, not final. The blood and tissue findings were only a first look. The trial took place at just one center. With no second group, the trial can't show the mix beats usual care.
Source
Ivonescimab plus chemotherapy as first-line treatment for advanced thymic carcinoma: preliminary results of a phase II trial with biomarker analyses.
PubMed · PMID 42778290We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Thymoma and thymic carcinoma publications